Powerhouse surges on contract win
Powerhouse Energy, the AIM listed clean energy company, surged on news of a sale by its 30% owned subsidiary Pyromex AG.
Powerhouse Energy, the AIM listed clean energy company, surged on news of a sale by its 30% owned subsidiary Pyromex AG.
Pyromex has signed a sales contract and received an initial payment for a 5-ton per day ultra-high temperature, zero emission gasification reactor from the Italian firm Primula SRL.
The Primula contract is valued at approximately €2,000,000.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Primula's feedstock of wood clippings will be pelletized and then gasified using the Pyromex reactor to produce clean syngas.
The syngas will fuel a gas engine with an output capacity of 500 kWh.
Ross Lyndon-James, Executive Chairman of PowerHouse, said:
"This second sale by Pyromex is further validation of the broad spectrum of feedstock the system can operate on and demonstrates the application of the Pyromex reactor for industrial applications."
Powerhouse has an option to purchase the remaining 70% of Pyromex. Over the last 12 months the stock has gained 355%. The shares rose 1.125p to 22.75p on news of the sale.
BS
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
-
Energy bills to rise by 1.2% in January 2025
Energy bills are set to rise 1.2% in the New Year when the latest energy price cap comes into play, Ofgem has confirmed
By Dan McEvoy Published
-
Should you invest in Trainline?
Ticket seller Trainline offers a useful service – and good prospects for investors
By Dr Matthew Partridge Published